


## HOW TO END CANCER

1 Sensitive diagnostic for stage 1 cancers →



Calviri solves the stage 1 sensitivity problem

2 Premade vaccine to treat multi-cancers →



Premade vaccines treat, broadly & inexpensively

## INVESTMENT STORY

### Mission

To use our technologies to develop products that end cancers worldwide.

### Science & Technologies

**Diagnostics:** We have invented a universal diagnostic chip that solves the sensitivity problem for stage 1 cancer detection. It is based on assaying the antibody responses to tumor neoantigens.

**Peptide Chip Production:** We have adapted semi-conductor instruments to manufacture our highly scalable peptide chips for diagnostics.

**Vaccines:** Calviri has discovered a new source of tumor neoantigens- from mRNA errors- that are shared between patients and cancer types. This discovery enables production of off-the-shelf, inexpensive therapeutic and preventative vaccines. **Our recently completed 800 pet dog, 5 yr clinical trial showed a vaccine made of these antigens can prevent cancer.**

### Milestones Accomplishments

- Published pre-clinical studies validating vaccine platform
- Established scalable manufacturing of diagnostic chips
- Collected largest bank of blood from pets with stage 1 tumors
- Validated diagnostic sensitivity and specificity for stage 1 tumor detection
- Created proprietary database of all human and pet mRNA-derived neoantigens
- Developed a process for functionally screening for immunogenic, shared neoantigens for vaccines
- Completed 800+ dog 5 year trial showing safety and efficacy of our vaccines

### Technology protection

- >60 Patents issued and pending
- Moat of in-house secrets for chip production
- Issued patents on methods and compositions of diagnostics and vaccines

## US MARKET POTENTIALS

Products	Annual Sales
Dog Diagnostics	\$4B
Dog Therapeutic Vaccines	\$3.5B

## BOARD OF DIRECTORS

Jeffery Le Bengier MD | Chairman, Former CEO Summit Health

Jacque Sokolov MD | CEO SSB Solutions

Michael McCallister | Chairman for Zoetis Board

Stephen Albert Johnston | CEO, Co-Founder

Kathryn Sykes PhD | VP Research & Product Devt, Co-Founder

## SCIENTIFIC ADVISORY BOARD

Terry A. McInnis, MD, MBA, MPH | Chairman  
Senior Healthcare Advisor & Consultant

Stan Lapidus | Founder Cytyc and Exact Sciences

John Ballantyne, PhD | Co-founder Aldebron

Steven W. Dow, DVM, PhD | Director of Immunotherapy Laboratory  
College of Veterinary Medicine, Colorado State University

Peter P. Lee MD | Director of Immunotherapy Laboratory

## BUSINESS PLAN & TIMELINE

Calviri will commercialize its dog diagnostics and vaccines starting in 2025. Diagnostics will be licensed to strategics for commercialization; vaccines will be retained and commercialized by Calviri directly.

2025	2026	2027
Initiated Canine HSA Therapeutic Vaccine Trial	Commercialize Canine Diagnostic	Initiate Canine Multi-cancer Therapeutic Vaccine Trial
		Commercialize Canine Preventative Vaccine
		Commercialize Canine Therapeutic Vaccine

## REVENUE STREAM

	2025	2026	2027
Dog Diagnostic	\$11.9M (Licenses)	\$19M (Licenses + Sales)	\$150M (Licenses + Sales)
Dog Therapeutic Vaccine			\$20M (Sales)
Dog Preventative Vaccine		\$2.5M (Sales)	\$25M (Sales)

All Calviri Animal Health technologies can be applied to human diagnostics and vaccines

Contact Details

Stephen Albert Johnston  
Stephen.johnston@calviri.com

info@calviri.com  
850 N 5th St. Phoenix, AZ